Results 271 to 280 of about 414,897 (392)

Is highly purified cannabidiol a treatment opportunity for drug‐resistant epilepsy in subjects with typical Rett syndrome and CDKL5 deficiency disorder?

open access: yesEpilepsia Open, EarlyView.
Abstract Objective This study aimed to evaluate the efficacy and safety of adjunctive, highly purified Cannabidiol (Epidiolex®) in individuals with drug‐resistant epilepsy (DRE) due to genetically determined typical Rett Syndrome (RTT) and CDKL5 Deficiency Disorder (CDD). Methods We recruited subjects with genetically confirmed typical RTT and CDD with
Aglaia Vignoli   +22 more
wiley   +1 more source

Respiratory Syncytial Virus Vaccine Induced Thrombotic Microangiopathy. [PDF]

open access: yesJ Blood Med
Seby R   +8 more
europepmc   +1 more source

Efficacy and tolerability of fenfluramine with concomitant potassium bromide in patients with Dravet syndrome

open access: yesEpilepsia Open, EarlyView.
Abstract Objective To assess the efficacy and tolerability of fenfluramine (FFA) with concomitant potassium bromide (BR) in patients with Dravet syndrome (DS). Methods This multicenter retrospective study, conducted within the German compassionate use program, analyzed BR doses and serum levels before and after FFA initiation, adverse events (AEs ...
Milka Pringsheim   +13 more
wiley   +1 more source

SCN1A gain of function effects in Dravet syndrome: Insights into clinical phenotypes and therapeutic implications

open access: yesEpilepsia Open, EarlyView.
Abstract A large number of cases with Dravet syndrome (DS) has been attributed to SCN1A loss of function (LOF), whereas SCN1A gain‐of‐function (GOF) causes early infantile developmental and epileptic encephalopathy (EIDEE) and familial hemiplegic migraine 3.
Yoko Kobayashi Takahashi   +13 more
wiley   +1 more source

Long‐term treatment with carbamazepine restores cognitive abilities in a mouse model of KCNQ2 developmental and epileptic encephalopathy

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Carbamazepine is the first line treatment for patients affected by KCNQ2 developmental and epileptic encephalopathy. It is efficient to reduce or stop seizures in this context. However, its effect on the neurodevelopmental outcomes is debated.
Jordane Louis   +7 more
wiley   +1 more source

Blood-brain barrier dysfunction in acute lead encephalopathy: a reappraisal.

open access: diamond, 1975
Thomas W. Bouldin   +3 more
openalex   +1 more source

Home - About - Disclaimer - Privacy